Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | F2R | P25116 | 13/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16270629 | 0.89 | KMT2A (0.58) | KMT2AMEN1F2RNPC1RAB9A | |
| SCHEMBL23070709 | 0.87 | KMT2A (0.68) | KMT2AMEN1F2RNPC1RAB9A | |
| SCHEMBL10069451 | 0.85 | KMT2A (0.79) | KMT2AMEN1F2RNPC1RAB9A | |
| SCHEMBL5668584 | 0.84 | FADS1 (0.62) | KMT2AMEN1ALDH1A1PARP1PARP15 | |
| SCHEMBL18132551 | 0.84 | ALDH1A1 (0.65) | KMT2AMEN1ALDH1A1PARP1PARP15 | |
| SCHEMBL2683831 | 0.82 | MEN1 (0.64) | KMT2AMEN1ALDH1A1RXFP1PARP1 | |
| SCHEMBL27654215 | 0.82 | MEN1 (0.74) | KMT2AMEN1F2RNPC1RAB9A | |
| SCHEMBL13894163 | 0.82 | TDP1 (0.58) | KMT2AMEN1ALDH1A1PARP1PARP15 | |
| SCHEMBL14818771 | 0.82 | KCNK3 (0.74) | KMT2AMEN1F2RRAB9AALDH1A1 | |
| SCHEMBL810165 | 0.82 | ALDH1A1 (0.68) | KMT2AF2RNPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212290-B1 | ARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMA (US) | 2014-12-03 | — | — | EP | disclosed |
| US-8779197-B2 | Aryl amides useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-15 | — | — | US | disclosed |
| US-8779197-B2 | Aryl amides useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-15 | — | — | US | disclosed |
| US-8779197-B2 | Aryl amides useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-15 | — | — | US | disclosed |
| EP-2212290-A1 | ARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2010-08-04 | — | — | EP | disclosed |
| US-20090118338-A1 | ARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-07 | — | — | US | disclosed |
| US-20090118338-A1 | ARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-07 | — | — | US | disclosed |
| US-20090118338-A1 | ARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-07 | — | — | US | disclosed |
| WO-2009049183-A1 | ARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009049183-A1 | ARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118338-A1 | ARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | KCNH2, KCNH3, SCN5A | KMT2A 1218/4885MEN1 3792/4885F2R 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.